China, Jiangsu, Department of Endocrinology
Xuzhou, 221006, China
Location status: Recruiting
Location contact
Hongwei Ling, MD
CONTACT
Renguo Chen, MD
PRINCIPAL_INVESTIGATOR
Yuhan Huang, MD
SUB_INVESTIGATOR
NCT Number: NCT06277466
In this study, investigators wanted to determine the effect of T2DM susceptibility gene mutations on self-expression.
Participants (T2DM patients and controls) were recruited to identify genotypes and detect the levels of T2DM susceptibility genes expression in the fresh peripheral plasma. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were also collected to identify the expression differences of T2DM susceptibility genes under different genotypes.
Interested in participating?
Request Info25 year–70 year
All sexes
Interventional
Not applicable
Xuzhou, 221006, China
Location status: Recruiting
Hongwei Ling, MD
CONTACT
Renguo Chen, MD
PRINCIPAL_INVESTIGATOR
Yuhan Huang, MD
SUB_INVESTIGATOR
The primary objective of this study was to investigate the changes of the expression of T2DM susceptible genes (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) in participants (newly diagnosed T2DM patients and controls) after gene mutation.
Secondly, the expression differences of T2DM susceptible genes in T2DM patients with different genotypes were compared, and the relationship between the expression differences and clinicopathological characteristics of T2DM patients was analyzed.
Participants (newly diagnosed T2DM patients and healthy subjects) were screened from the department of endocrinology and health management center, whose fresh peripheral blood were collected. The normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected in the department of general surgery. The DNA genome was extracted for genotyping, and then the expression levels of T2DM related susceptibility genes under different genotypes were detected by ELISA kits, PCR, WB,HE staining, IHC staining, ect.
The basic information of T2DM patients was collected, including demographic characteristics, physiological and biochemical data.Then investigators further compared the differences in the expression of susceptible genes between newly diagnosed T2DM patients and controls.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Compared with newly diagnosed T2DM patients, healthy subjects in the control group had normal levels of blood glucose, lipids, glycated hemoglobin levels, etc. Fresh normal pancreatic tissues or adjacent tissues of pancreatic cancer were collected before taking antidiabetic drugs in both groups.
The newly diagnosed T2DM group should not have taken antidiabetic drugs and meet the diagnosis of T2DM. Fresh blood samples were collected before medication for detection.
In the control group (healthy subjects), the indicators of physical examination were within the normal range and no hypoglycemic drugs were taken. Similarly, fresh blood samples should be taken for testing.
Time frame: 1 month after fresh sample collection
To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of newly diagnosed T2DM patients and compared with those in healthy subjects.
Time frame: 1 month after fresh sample collection
To detect the expression levels of susceptible genes in the plasma and the pancreatic tissues of controls and compared with those in newly diagnosed T2DM patients.
Time frame: 6 months after obtaining the clinicopathological results
Incidence of clinical pancreatic diseases under expression differences in T2DM susceptibility genes
Time frame: 1 month of completion for individual screening
Baseline BMI of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline WHR of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline FPG of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline HbA1c of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline TC of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline TG of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline HDL-C of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline LDL-C of newly diagnosed with T2DM patients
Time frame: 1 month of completion for individual screening
Baseline BMI of controls
Time frame: 1 month of completion for individual screening
Baseline WHR of controls
Time frame: 1 month of completion for individual screening
Baseline FPG of controls
Time frame: 1 month of completion for individual screening
Baseline HbA1c of controls
Time frame: 1 month of completion for individual screening
Baseline TC of controls
Time frame: 1 month of completion for individual screening
Baseline TG of controls
Time frame: 1 month of completion for individual screening
Baseline HDL-C of controls
Time frame: 1 month of completion for individual screening
Baseline LDL-C of controls
Contact information is provided by the study sponsor or research team.
Tao Wang, Ph.D
CONTACT
Xiaoxing Yin, Ph.D
CONTACT
The Affiliated Hospital of Xuzhou Medical University
Other
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06256419
Diabetes Mellitus, Diabetes Mellitus, Type 2
Xuzhou, China
View Trial DetailsNCT07351058
Body Weight, Diabetes Mellitus
Guntersville, Alabama, United States
View Trial DetailsNCT07711171
Cognition Disorders, Cognitive Dysfunction
Shanghai, Shanghai Municipality, China
View Trial DetailsNCT07662044
Diabetes Mellitus, Diabetes Mellitus, Type 2
Birmingham, Alabama, United States
View Trial Details